^
    1year
    Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues. (PubMed, Front Vet Sci)
    We found that all 23 CAAs showed diffuse and strong membranous RAS Q61R immunoreactivity (100% sensitivity), while none of the 8 OSCCs showed immunoreactivity (100% specificity). The data supports the use of RAS Q61R-specific rabbit monoclonal antibody for diagnostic IHC confirmation of CAA and ruling out OSCC in dogs.
    Journal
    |
    BRAF (B-raf proto-oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    BRAF mutation • HRAS mutation • NRAS Q61R • NRAS Q61L • HRAS Q61L • BRAF V595E • HRAS Q61R
    over1year
    RAS gene mutations and histomorphometric measurements in oral squamous cell carcinoma. (PubMed, Biotech Histochem)
    Our findings suggest that KRAS may be mutated more frequently in OSCC compared to HRAS and NRAS. Also, the histological features of nuclear and cellular diameter differed significantly between the KRAS mutated and unmutated cases.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • RAS mutation • HRAS mutation • NRAS Q61 • KRAS G12S • KRAS Q61H • NRAS G12 • NRAS Q61L • HRAS Q61L • HRAS G12S • KRAS Q61L • NRAS G12S
    2years
    HRAS Alteration Is Retained in the Heterogeneous Components of the Non-Invasive Upper Tract Urothelial Carcinoma (AMP 2022)
    HRAS mutation, a well-known genetic alteration of low-grade tumor in bladder cancer, was detected only in the high-grade UTUC in the public data, suggesting a rather distinct molecular alteration of UTUC. Also, HRAS alteration was clonally retained in not only the low-grade but also the high-grade components, and was significantly correlated to intratumoral heterogeneity. Our findings can help understand the underlying biology of NI-UTUC cases with HRAS alteration and intratumoral heterogeneity.
    HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS mutation • NRAS Q61R • NRAS Q61L • HRAS Q61L • HRAS Q61R
    over2years
    HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. (PubMed, Curr Oncol)
    The clinical course of patients with HRAS-mutant NSCLC remains unclear. Furthers cases should be identified in order to clarify prognosis and response to therapies. Tipifarnib, a farnesyl transferase inhibitor, is a promising candidate to target HRAS-mutant tumours and should be explored in NSCLC patients.
    Clinical • Review • Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    HRAS mutation • NRAS Q61L • HRAS Q61L
    |
    Zarnestra (tipifarnib)
    over3years
    Composite pheochromocytoma/paraganglioma-ganglioneuroma: analysis of SDH and ATRX status and identification of frequent HRAS and BRAF mutations. (PubMed, Endocr Connect)
    We demonstrated that composite PCC/PGL-GN might be a unique entity with frequent HRAS and BRAF mutations rather than genetic changes of SDH and ATRX. Our findings revealed the possible pathogenesis of composite PCC/PGL-GN and provided clues for potential treatment targets.
    Journal
    |
    BRAF (B-raf proto-oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • ATRX (ATRX Chromatin Remodeler) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    BRAF mutation • HRAS mutation • HRAS G13R • NRAS Q61R • BRAF K601E • NRAS Q61L • HRAS Q61L • HRAS Q61R • HRAS G13R • BRAF K601